GREY:ATBPF - Post by User
Post by
Yassinon Mar 31, 2020 10:59pm
317 Views
Post# 30866920
Earlier Phase 2A, WOMAC pain score reduction of 7.6 units
Earlier Phase 2A, WOMAC pain score reduction of 7.6 unitsearlier Phase 2A open label, efficacy study that was concluded in August 2016. The primary endpoint of that study was the clinical assessment of pain measured at three time points over the ten day course of treatment at 250 mg once daily (n = 12). This produced a WOMAC pain score reduction of 7.6 units on day 10, at a very high level of statistical significance in comparison to baseline pain (p<0.001). In contrast, published studies have provided evidence that the average reduction of WOMAC pain scores observed with the most commonly prescribed NSAIDs (naproxen and celecoxib) for treating OA is ~4 units.